0001906324-23-000056.txt : 20231101 0001906324-23-000056.hdr.sgml : 20231101 20231101161205 ACCESSION NUMBER: 0001906324-23-000056 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231101 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231101 DATE AS OF CHANGE: 20231101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QuidelOrtho Corp CENTRAL INDEX KEY: 0001906324 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 874496285 FISCAL YEAR END: 0101 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41409 FILM NUMBER: 231368383 BUSINESS ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 552-1100 MAIL ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Coronado Topco, Inc. DATE OF NAME CHANGE: 20220124 8-K 1 qdel-20231101.htm 8-K qdel-20231101
0001906324false00019063242023-11-012023-11-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 1, 2023

QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)

Delaware
001-41409

87-4496285
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

9975 Summers Ridge Road, San Diego, California 92121
(Address of principal executive offices, including zip code)
(858552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 2.02    Results of Operations and Financial Condition.

On November 1, 2023, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its third quarter ended October 1, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 1, 2023 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.

The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01    Financial Statements and Exhibits.
 (d)    Exhibits.
 The following exhibit is furnished with this Form 8-K:
  
Exhibit NumberDescription of Exhibit
99.1
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 1, 2023
   
QUIDELORTHO CORPORATION
  
By:/s/ Joseph M. Busky 
Name:Joseph M. Busky 
Its:Chief Financial Officer 


EX-99.1 2 qdel10012023ex991earningsr.htm EX-99.1 Document
Exhibit 99.1

qographica.jpg

November 1, 2023

QuidelOrtho Reports Third Quarter 2023 Financial Results

Broad strength in respiratory and core businesses across all geographies, driven by execution, customer excellence and improved operational efficiencies

Highlights

Third quarter revenue was $744 million, as reported, driven by strong respiratory demand and continued strength in non-respiratory businesses
Non-respiratory revenue increased by 2% as reported and in constant currency, compared to the prior year period, driven by growth in the Labs business, which continues to perform to expectations
Respiratory revenue decreased by 21% as reported and in constant currency, primarily due to the anticipated decline in COVID-19 revenue compared to the prior year period
Growth across all geographies, including continued strength in China, excluding COVID-19
Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90
GAAP net loss was $(13) million; adjusted EBITDA was $169 million; adjusted EBITDA margin was 23%, up from 17% in the second quarter of 2023
GAAP net cash provided by operating activities was $42 million; adjusted free cash flow was $53 million; the Company paid down $52 million on its term loan during the third quarter of 2023; year to date, the Company has paid down a total of $175 million of debt

San Diego, CA — QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 1, 2023.

“We finished the third quarter strong, with solid financial performance across all geographies. Our results were driven by higher-than-expected respiratory demand coupled with the strength of our Labs business and improved operational efficiencies,” said Douglas Bryant, President and Chief Executive Officer, QuidelOrtho. “The rise of multiple circulating viruses demonstrates the need for fast, accurate, multiplexed syndromic testing solutions like Savanna, which we continue to make steady progress on. As respiratory viruses persist, our portfolio of diagnostic products uniquely positions us to serve patients and clinicians around the world. Looking toward the end of the year, we anticipate a solid finish.”
The Company reported total revenue for the third quarter of 2023 of $744.0 million, compared to $783.8 million for the third quarter of 2022. Foreign currency translation did not significantly impact third quarter 2023 results. GAAP diluted loss per share for the third quarter of 2023 was $(0.19), compared to diluted EPS of $0.28 for the third quarter of 2022. GAAP operating income for the third quarter of 2023 was $26.3 million, compared to operating income of $56.8 million for the third quarter of 2022, and GAAP operating margin was 4% and 7% for the third quarters of 2023 and 2022, respectively. Third quarter 2023 results included $26.5 million in integration-related charges.

Adjusted diluted EPS for the third quarter of 2023 was $0.90, compared to $1.85 in the prior year period. Adjusted EBITDA for the third quarter of 2023 was $169.2 million, compared to $226.8 million in the prior year period. Adjusted EBITDA margin for the third quarter of 2023 was 23%, compared to 29% in the prior year period. The year-over-year change in adjusted EPS and adjusted EBITDA was primarily related to the anticipated decline in COVID-19 revenue compared to the prior year period.



qographica.jpg
Fiscal Year 2023 Financial Guidance

The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows:
Total revenues (reported)$2.88 - $3.08 billion
Non-respiratory revenue$2.27 - $2.31 billion
Respiratory revenue$610 - $775 million
Adjusted EBITDA$800 - $830 million
Adjusted EBITDA %26.9% - 27.7%
Adjusted diluted EPS$4.85 - $5.30

Conference Call Information

QuidelOrtho will hold a conference call today at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results for the third quarter ended October 1, 2023. Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/. Presentation materials will also be posted to the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or 929-526-1599 (international) and entering Conference ID number 697176.

A replay of the conference call will be available shortly after the event on the “Investor Relations” page of the Company’s website, under the “Events & Presentations” section.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

QuidelOrtho is advancing diagnostics to power a healthier future.

For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation



qographica.jpg
Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho’s commercial, integration, transformation and other strategic goals, financial guidance and other future financial and operating results, and future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words “may,” “will,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue” or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of today and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements: the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the business combination (the “Combinations”) of Quidel Corporation (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”); supply chain, production, logistics, distribution and labor disruptions and challenges; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those discussed under Part I, Item 1A, “Risk Factors” of QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023 and subsequent reports filed with the Securities and Exchange Commission (the “Commission”). You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

Supplemental Combined Financial Measures

This press release contains unaudited supplemental combined financial information (“Supplemental Combined Information”) that gives effect to the Combinations as if Quidel and Ortho had been combined for the applicable periods. Certain Supplemental Combined Information presented is based on the historical financial statements of Quidel and Ortho with reclassification adjustments only and do not include all of the pro forma adjustments required under Regulation S-X Article 11 or Accounting Standards Codification 805, Business Combinations (“ASC 805”). The Supplemental Combined Information is provided for illustrative purposes only, may be updated in the future, and is not necessarily, and should not be assumed to be, indicative of the Company’s expected results of operations or financial position that would have been achieved had the Combinations been completed as of the dates indicated or that may be achieved in any future period. The Supplemental Combined Information should be considered supplemental to, and not as a substitute for, pro forma financial information prepared in accordance with Regulation S-X Article 11 or ASC 805 and should be read in conjunction with the information contained in the sections entitled “The Combinations,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Ortho” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Quidel” in QuidelOrtho’s joint proxy statement/prospectus (the “Joint Proxy Statement/Prospectus”) filed with the Commission on April 11, 2022 and the historical consolidated financial statements and related notes appearing elsewhere in, or incorporated into, the Joint Proxy Statement/Prospectus, and the Company’s subsequent reports filed with the Commission. The Company’s actual results of operations and financial position will differ, potentially significantly, from the Supplemental Combined Information reflected in this press release as a result of the methodology used to prepare the Supplemental Combined Information as well as a variety of factors, including but not limited to the effect of certain expected financial benefits of the Combinations (such as revenue and cost synergies), the anticipated costs to achieve these benefits (including the cost of integration activities), tax impacts, and changes in operating results following the date of this press release.



qographica.jpg
Non-GAAP Financial Measures

This press release contains financial measures, including but not limited to “constant currency” revenue changes, “adjusted net income,” “adjusted diluted EPS,” “adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted free cash flow,” “supplemental combined adjusted net income,” “supplemental combined adjusted diluted EPS,” “supplemental combined adjusted EBITDA” and “supplemental combined revenues by business unit and region,” which are considered non-GAAP financial measures under applicable rules and regulations of the Commission. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). “Adjusted net income,” “adjusted diluted EPS,” “adjusted EBITDA,” “adjusted EBITDA margin” and “adjusted free cash flow” eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. The Company believes that “supplemental combined adjusted net income,” “supplemental combined adjusted diluted EPS,” “supplemental combined adjusted EBITDA” and “supplemental combined revenues by business unit and region” provide helpful Supplemental Combined Information to assist management and investors in evaluating the Company’s adjusted operating results as if Quidel and Ortho had been combined for the applicable periods. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the non-GAAP financial measures, including the non-GAAP Supplemental Combined Information, to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@quidelortho.com

Media Contact:
Stephanie Kleewein
Communications Manager
media@quidelortho.com


qographica.jpg

QuidelOrtho
Consolidated Statements of Operations
(Unaudited)
(In millions except per share data)

 Three Months EndedNine Months Ended
 
October 1, 2023 (a)
October 2, 2022 (b)
October 1, 2023 (a)
October 2, 2022 (b)
Total revenues$744.0 $783.8 $2,255.2 $2,399.5 
Cost of sales, excluding amortization of intangibles375.9 376.3 1,142.1 912.5 
Selling, marketing and administrative194.1 204.2 575.6 407.4 
Research and development62.4 65.6 187.5 126.2 
Amortization of intangible assets51.4 50.5 153.6 78.6 
Acquisition and integration costs26.5 26.4 80.4 109.6 
Other operating expenses7.4 4.0 17.0 8.0 
Operating income26.3 56.8 99.0 757.2 
Interest expense, net37.7 29.7 110.9 41.0 
Loss on extinguishment of debt— — — 24.0 
Other expense (income), net4.1 (4.2)8.0 (2.6)
(Loss) income before income taxes(15.5)31.3 (19.9)694.8 
(Benefit from) provision for income taxes(2.8)12.1 (2.8)176.4 
Net (loss) income$(12.7)$19.2 $(17.1)$518.4 
Basic (loss) earnings per share$(0.19)$0.29 $(0.26)$9.67 
Diluted (loss) earnings per share$(0.19)$0.28 $(0.26)$9.56 
Weighted-average shares outstanding - basic66.9 66.9 66.8 53.6 
Weighted-average shares outstanding - diluted66.9 67.5 66.8 54.2 

(a) Includes Ortho results of operations for the three and nine months ended October 1, 2023.
(b) Includes Ortho results of operations for the three months ended October 2, 2022 and from May 27, 2022 through October 2, 2022 for the nine months ended October 2, 2022.


qographica.jpg

QuidelOrtho
Condensed Consolidated Balance Sheets
(Unaudited)
(In millions)

October 1, 2023January 1, 2023
Cash and cash equivalents$149.3 $292.9 
Marketable securities43.9 52.1 
Accounts receivable, net331.2 453.9 
Inventories551.7 524.1 
Prepaid expenses and other current assets295.2 252.1 
Property, plant and equipment, net1,369.4 1,339.0 
Marketable securities11.9 21.0 
Right-of-use assets172.2 181.0 
Goodwill2,442.9 2,476.8 
Intangible assets, net2,976.5 3,123.8 
Deferred tax asset15.7 16.4 
Other assets179.2 122.7 
Total assets$8,539.1 $8,855.8 
Accounts payable$253.0 $283.3 
Accrued payroll and related expenses106.8 139.2 
Income tax payable1.8 51.6 
Current portion of borrowings193.0 207.5 
Other current liabilities305.4 325.4 
Operating lease liabilities175.9 186.4 
Long-term borrowings2,274.6 2,430.8 
Deferred tax liability196.5 213.2 
Other liabilities65.4 83.8 
Total liabilities3,572.4 3,921.2 
Total stockholders’ equity4,966.7 4,934.6 
Total liabilities and stockholders’ equity$8,539.1 $8,855.8 




qographica.jpg

QuidelOrtho
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In millions)

Nine Months Ended
October 1, 2023 (a)
October 2, 2022 (b)
Cash provided by operating activities$199.8 $715.9 
Cash used for investing activities(132.5)(1,584.9)
Cash (used for) provided by financing activities(208.0)283.7 
Effect of exchange rates on cash(3.3)(4.3)
Net decrease in cash, cash equivalents and restricted cash(144.0)(589.6)
Cash, cash equivalents and restricted cash at beginning of period293.9 802.8 
Cash, cash equivalents and restricted cash at end of period$149.9 $213.2 
Reconciliation to amounts within the consolidated balance sheets:
Cash and cash equivalents$149.3 $212.2 
Restricted cash in Other assets0.6 1.0 
Cash, cash equivalents and restricted cash$149.9 $213.2 

(a) Includes Ortho activities for the nine months ended October 1, 2023.
(b) Includes Ortho activities from May 27, 2022 through October 2, 2022.


qographica.jpg

QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted Net Income
(In millions, except per share data; unaudited)

Three Months EndedNine Months Ended
October 1, 2023 (a)
Diluted EPS
October 2, 2022 (b)
Diluted EPS
October 1, 2023 (a)
Diluted EPS
October 2, 2022 (b)
Diluted EPS
Net (loss) income$(12.7)$(0.19)$19.2 $0.28 $(17.1)$(0.26)$518.4 $9.56 
Adjustments:
Amortization of intangibles51.4 50.5 153.6 78.6 
Acquisition and integration costs26.5 26.4 80.4 109.6 
Incremental depreciation on PP&E fair value
   adjustment
8.2 1.3 25.3 1.3 
Amortization of deferred cloud computing
   implementation costs
2.8 1.6 5.9 3.9 
Impairment of long-lived assets2.2 — 3.2 — 
Loss on investments1.0 — 1.2 0.8 
EU medical device regulation transition costs0.4 0.6 1.9 1.0 
Unwind inventory fair value adjustment— 35.4 — 46.6 
Employee compensation charges— 1.0 — 1.5 
Noncash interest expense for deferred
   consideration
— 0.6 0.7 2.3 
Loss on extinguishment of debt— — — 24.0 
Derivative mark-to-market gain— (3.4)— (4.4)
Other adjustments1.1 0.3 2.6 0.4 
Income tax impact of adjustments(20.2)(9.0)(57.5)(46.5)
Discrete tax items— 0.6 (1.1)0.6 
Adjusted net income$60.7 $0.90 $125.1 $1.85 $199.1 $2.96 $738.1 $13.62 
Ortho pre-combination adjusted net income— — — 77.2 
Supplemental combined adjusted net income$60.7 $0.90 $125.1 $1.85 $199.1 $2.96 $815.3 $11.99 
Weighted-average shares outstanding - diluted67.3 67.5 67.3 54.2 
Weighted-average shares outstanding - diluted -
   supplemental combined
67.3 67.5 67.3 68.0 
(a) Adjusted net income includes Ortho activities for the three and nine months ended October 1, 2023.
(b) Adjusted net income includes Ortho activities for the three months ended October 2, 2022 and from May 27, 2022 through October 2, 2022 for the nine months ended October 2, 2022.


qographica.jpg


QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA
(In millions, unaudited)

Three Months EndedNine Months Ended
October 1, 2023 (a)
October 2, 2022 (b)
October 1, 2023 (a)
October 2, 2022 (b)
Net (loss) income$(12.7)$19.2 $(17.1)$518.4 
Depreciation and amortization113.1 104.2 341.8 167.0 
Interest expense, net37.7 29.7 110.9 41.0 
(Benefit from) provision for income taxes(2.8)12.1 (2.8)176.4 
Acquisition and integration costs26.5 26.4 80.4 109.6 
Amortization of deferred cloud computing
   implementation costs
2.8 1.6 5.9 3.9 
Impairment of long-lived assets2.2 — 3.2 — 
Loss on investments1.0 — 1.2 0.8 
EU medical device regulation transition costs0.4 0.6 1.9 1.0 
Unwind inventory fair value adjustment— 35.4 — 46.6 
Employee compensation charges— 1.0 — 1.5 
Loss on extinguishment of debt— — — 24.0 
Derivative mark-to-market gain— (3.4)— (4.4)
Tax indemnification income(0.1)(0.3)(0.2)(0.3)
Other adjustments1.1 0.3 2.6 0.4 
Adjusted EBITDA$169.2 $226.8 $527.8 $1,085.9 
Ortho pre-combination Adjusted EBITDA— — — 212.5 
Supplemental combined Adjusted EBITDA$169.2 $226.8 $527.8 $1,298.4 

(a) Adjusted EBITDA includes Ortho activities for the three and nine months ended October 1, 2023.
(b) Adjusted EBITDA includes Ortho activities for the three months ended October 2, 2022 and from May 27, 2022 through October 2, 2022 for the nine months ended October 2, 2022.


qographica.jpg

QuidelOrtho
Supplemental Combined Revenues by Business Unit and Region
(In millions, unaudited)

Three Months Ended
October 1, 2023October 2, 2022% ChangeCurrency Impact
Constant Currency (a)
Respiratory revenues$185.4 $236.1 (21.5)%— %(21.5)%
Non-Respiratory revenues558.6 547.7 2.0 %— %2.0 %
Total revenues$744.0 $783.8 (5.1)%— %(5.1)%

Three Months Ended
October 1, 2023October 2, 2022% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
Labs$341.4 $334.8 2.0 %— %2.0 %(1.3)%3.3 %
Transfusion Medicine163.9 163.1 0.5 %0.1 %0.4 %— %0.4 %
Point of Care233.1 270.5 (13.8)%— %(13.8)%(12.9)%(0.9)%
Molecular Diagnostics5.6 15.4 (63.6)%0.1 %(63.7)%(57.2)%(6.5)%
Total revenues$744.0 $783.8 (5.1)%— %(5.1)%(7.1)%2.0 %

Three Months Ended
October 1, 2023October 2, 2022% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
North America$465.2 $517.6 (10.1)%(0.4)%(9.7)%(8.7)%(1.0)%
EMEA74.5 73.7 1.1 %3.5 %(2.4)%(5.2)%2.8 %
China81.1 80.8 0.4 %(5.1)%5.5 %(0.1)%5.6 %
Other123.2 111.7 10.3 %3.3 %7.0 %(0.3)%7.3 %
Total revenues$744.0 $783.8 (5.1)%— %(5.1)%(7.1)%2.0 %

(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as substitute for financial information prepared in accordance with GAAP.


qographica.jpg
Nine Months Ended
October 1, 2023October 2, 2022% ChangeCurrency Impact
Constant Currency (a)
Respiratory revenues$540.0 $1,522.5 (64.5)%— %(64.5)%
Non-Respiratory revenues1,715.2 1,662.2 3.2 %(1.1)%4.3 %
Total supplemental combined revenues (b)
$2,255.2 $3,184.7 (29.2)%(0.1)%(29.1)%

Nine Months Ended
October 1, 2023October 2, 2022% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
Labs (b)
$1,073.5 $1,016.5 5.6 %(1.1)%6.7 %(2.3)%9.0 %
Transfusion Medicine483.1 505.6 (4.5)%(1.1)%(3.4)%— %(3.4)%
Point of Care675.4 1,580.5 (57.3)%(0.1)%(57.2)%(57.7)%0.5 %
Molecular Diagnostics23.2 82.1 (71.7)%0.1 %(71.8)%(57.7)%(14.1)%
Total supplemental combined revenues (b)
$2,255.2 $3,184.7 (29.2)%(0.1)%(29.1)%(33.4)%4.3 %
Nine Months Ended
October 1, 2023October 2, 2022% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
North America$1,426.8 $2,351.1 (39.3)%(0.2)%(39.1)%(39.8)%0.7 %
EMEA236.4 240.6 (1.7)%(0.2)%(1.5)%(4.8)%3.3 %
China233.0 240.2 (3.0)%(4.5)%1.5 %(14.8)%16.3 %
Other359.0 352.8 1.8 %(0.4)%2.2 %(6.0)%8.2 %
Total supplemental combined revenues (b)
$2,255.2 $3,184.7 (29.2)%(0.1)%(29.1)%(33.4)%4.3 %

Supplemental combined revenues for the prior period in the tables above include Ortho revenues as if the acquisition had occurred on January 2, 2022.
(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as substitute for financial information prepared in accordance with GAAP.
(b) The nine months ended October 1, 2023 includes an approximate $19 million settlement award from a third party related to one of the Company’s collaboration agreements.


qographica.jpg
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted Free Cash Flow
(In millions, unaudited)

Three Months Ended
October 1, 2023
Net cash provided by operating activities$41.5 
Adjustments:
Capital expenditures(32.7)
Other payments (a)
44.0 
Adjusted free cash flow $52.8 

(a) Other payments include $23 million related to acquisition, integration and other costs, $16 million of integration-related cloud computing implementation costs and $5 million of other integration-related capital expenditures.

EX-101.SCH 3 qdel-20231101.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 qdel-20231101_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 qdel-20231101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Address Type [Domain] Address Type [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 qdel-20231101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 qographica.jpg begin 644 qographica.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information Document
Nov. 01, 2023
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Nov. 01, 2023
Entity Incorporation, State or Country Code DE
Entity File Number 001-41409
Entity Tax Identification Number 87-4496285
Entity Address, Address Line One 9975 Summers Ridge Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 552-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol QDEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001906324
Amendment Flag false
Entity Registrant Name QUIDELORTHO CORP
XML 9 qdel-20231101_htm.xml IDEA: XBRL DOCUMENT 0001906324 2023-11-01 2023-11-01 0001906324 false 8-K 2023-11-01 QUIDELORTHO CORP DE 001-41409 87-4496285 9975 Summers Ridge Road San Diego CA 92121 858 552-1100 false false false false Common Stock, $0.001 Par Value QDEL NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.quidel.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports qdel-20231101.htm qdel-20231101.xsd qdel-20231101_def.xml qdel-20231101_lab.xml qdel-20231101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "qdel-20231101.htm": { "nsprefix": "qdel", "nsuri": "http://www.quidel.com/20231101", "dts": { "inline": { "local": [ "qdel-20231101.htm" ] }, "schema": { "local": [ "qdel-20231101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "qdel-20231101_def.xml" ] }, "labelLink": { "local": [ "qdel-20231101_lab.xml" ] }, "presentationLink": { "local": [ "qdel-20231101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.quidel.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "qdel-20231101.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "qdel-20231101.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001906324-23-000056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001906324-23-000056-xbrl.zip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